Medical AI FDA Milestones and Risks
Key Questions
What is the FDA's AIM-NASH approval?
The FDA approved AIM-NASH, a milestone in medical AI for non-alcoholic steatohepatitis. It advances AI in diagnostics.
What advances are in oncology and CRC with AI?
AI shows AUC gains in oncology and colorectal cancer (CRC). Lunit presents studies at AACR 2026 on precision oncology applications.
What is Hippocratic AI's voice agents feature?
Hippocratic AI launched safety-first voice AI agents integrating EHRs for patients and nurses. Products like AI Front Door enhance clinical interactions.
What risks do medical chatbots pose?
Chatbots hallucinate amid 85M users, raising oversight concerns. State regs tighten on AI denials and governance.
How does OCT DL improve retinal screening?
OCT deep learning (DL) enhances generalizability for retinal screening. It supports broader medical imaging applications.
FDA AIM-NASH approval; oncology/CRC AUC gains; OCT DL generalizability for retinal screening; Hippocratic voice AI agents integrate EHRs. State regs tighten on oversight/denials; chatbots hallucinate amid 85M users.